Bharat Biotech recently stated it has submitted all of the information bearings on its COVID-19 vaccine Covaxin to the World health organization (WHO) for Emergency Use Listing (EUL) and is anticipating feedback from the global health watchdog.
The WHO is presently reviewing the information submitted by the vaccine maker and the date for a selection on the jab is yet “to be confirmed,” according to the update available on the WHO website. “#COVAXIN medical trial information was completely compiled & available in June 2021. All Data was submitted for Emergency Use Listing (EUL) Application to World Health Organization in early July. We have answered to any clarifications sought by #WHO and are anticipating similar remarks,” Bharat Biotech tweeted.
As an accountable producer with past approvals for its different vaccines, the employer stated it’d not find it suitable to take a position or comment on the approval process and its timelines, it similarly stated. “We are continuing to work diligently on acquiring WHO EUL on the earliest,” the vaccine maker added in a chain of tweets.
In a replacement on its website, the WHO stated it started out rolling information of the vaccine on July 6. Rolling information allows the WHO to begin its assessment proper away, as facts maintain to return in, to boost up the general assessment process. Suchitra Ella, joint dealing with the director of Bharat Biotech currently had in advance stated the EUL technique is a step towards the final selection on Covaxin’s ‘global acceptance
#COVAXIN® clinical trial data was fully Compiled & available in June 2021. All Data submitted for Emergency Use Listing (EUL) Application to World Health Organization in early July. (1/3) pic.twitter.com/r4CnROpUfP
— BharatBiotech (@BharatBiotech) September 17, 2021